Timing, hosts and locations of (grouped) events of NanoImpactNet

More documents

Recommendations

Info

NanoSafetyCluster - Compendium 2012 References [1] Hansen, S. F., Regulation and Risk Assessment of Nanomaterials. 2009, Technical University of Denmark: Lyngby. p. 130. [2] Yokoyama, M. 2005. Drug targeting with nano-sized carrier systems. J Artif Organs 8: 77-84. [3] Baumgartner, W., Jäckli, B., Schmithüsen, B. and Weber, F., Nanotechnology in der Medizin. 2003, Basics: Zürich. [4] Estella-Hermoso de Mendoza, A., Campanero, M. A., Mollinedo, F. and Blanco-Prieto, M. J. 2009. Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 5: 323-343. [5] Sokolov, K., Tam, J., Tam, J., Travis, K., Larson, T., Aaron, J., Harrison, N., Emelianov, S. and Johnston, K. 2009. Cancer imaging and therapy with metal nanoparticles. Conf Proc IEEE Eng Med Biol Soc 1: 2005-2007. [6] Surendiran, A., Sandhiya, S., Pradhan, S. C. and Adithan, C. 2009. Novel applications of nanotechnology in medicine. Indian J Med Res 130: 689-701. [7] Thomas, D. G., Pappu, R. V. and Baker, N. A. 2009. Ontologies for cancer nanotechnology research. Conf Proc IEEE Eng Med Biol Soc 1: 4158-4161. [8] Yeo, Y. and Xu, P. 2009. Nanoparticles for tumor-specific intracellular drug delivery. Conf Proc IEEE Eng Med Biol Soc 1: 2403-2405. [9] Colvin, V. L. 2003. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 21: 1166-1170. [10] Krug, H. "Auswirkungen nanotechnologischer Entwicklungen auf die Umwelt", http://www.scientificjournals.com/sj/uwsf/abstract/ArtikelId/7641, 2005. [11] Oberdörster, G. 2000. Toxicology of ultrafine particles: In vivo studies. Philosophical Transactions: Mathematical, Physical and Engineering Sciences (Series A) 2000: 2719-2740. [12] Oberdörster, G. 2001. Pulmonary effects of inhaled ultrafine particles. International Archives of Occupational and Environmental Health 74: 1-8. [13] Oberdörster, G., Elder, A., Gelein, R., Sharp, Z., Atudorei, V., Kreyling, W. and Cox, C. 2004. Translocation of inhaled ultrafine particles to the brain. Inhalation Toxicology 16: 437-445. [14] Oberdörster, G., Finkelstein, J. N., Johnston, C., Gelein, R., Cox, C., Baggs, R. and Elder, A. C. 2000. Acute pulmonary effects of ultrafine particles in rats and mice. Research report (Health Effects Institute) 5-74; disc. 75. [15] Oberdörster, G., Oberdörster, E. and Oberdörster, J. 2005. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives 113: 823-839. [16] Schuler, E. 2004. Zukunftsblick auf die Risikokommunikation im Bereich Nanotechnologie. IPTS Report [17] Journal, Ö. "Kleine Moleküle - große Erfolge, Europa soll in der Nanotechnologie weiter ganz vorne bleiben", www.oe-journal.at, 2005. [18] OECD, List of Manufactured Nanomaterials and List of Endpoints for Phase One of the OECD Testing Program, Directorate, Editor. 2008, OECD: Paris. p. 13. [19] OECD, Sponsorship Programm for the Testing of Manufactured Nanomaterials. 2009, OECD: Paris. p. 2. [20] Donaldson, K., Stone, V., Tran, C. L., Kreyling, W. and Borm, P. J. 2004. Nanotoxicology. Occup Environ Med 61: 727-728. 34 Compendium of Projects in the European NanoSafety Cluster
HINAMOX Health Impact of Engineered Metal and Metal Oxide Nanoparticles: Response, Bioimaging and Distribution at Cellular and Body Level Consortium: NanoSafetyCluster – Compendium 2012 Contract Agreement: NMP4-SL-2009-228825 - HINAMOX Website: http://www.hinamox.eu Coordinator: Sergio E. Moya, Centro de Investigación Cooperativa en Biomateriales – CIC biomaGUNE No. Beneficiary name Short name Country 1 Centro de Investigación Cooperativa en Biomateriales CIC biomaGUNE Spain 2 Universidad de Vigo UVIGO Spain 3 University of Leipzig ULEI Germany 4 Centro de Investigación en Química Aplicada CIQA Mexico 5 Zehjiang University ZJU China 6 PlasmaCHEM PLASMACHEM Germany 7 National Research Centre for the Working Environment NRCWE Denmark 8 Finish Institute of Occupational Health FIOH Finland Contents 1 Summary ..................................................................................... 36 2 Project Background .................................................................... 36 3 What is HINAMOX ...................................................................... 36 3.1 Project description .................................................................. 36 3.2 Partners ................................................................................... 39 3.3 Dissemination activities .......................................................... 40 3.4 Citations ................................................................................... 40 4 Directory ..................................................................................... 42 5 Copyright .................................................................................... 45 Compendium of Projects in the European NanoSafety Cluster 35
Page 1: Compendium of Projects in the Europ
Page 5 and 6: EDITED BY Michael Riediker, PD Dr.s
Page 7 and 8: CONTENTS NanoSafetyCluster - Compen
Page 9 and 10: Project Acronym ENNSATOX ENPRA EURO
Page 11 and 12: Foreword NanoSafetyCluster - Compen
Page 13 and 14: ENNSATOX ENgineered Nanoparticle Im
Page 15 and 16: The biological membrane and its dep
Page 17 and 18: distinguishes between the interacti
Page 19 and 20: Figure 10. Schematic representation
Page 21 and 22: WP5: • Permeability of NPs in hyd
Page 23 and 24: NanoSafetyCluster - Compendium 2012
Page 25 and 26: ENPRA RISK ASSESSMENT OF ENGINEERED
Page 27 and 28: vitro findings with in vivo models;
Page 29 and 30: protocols with real biological samp
Page 31 and 32: and it was organised in the frame o
Page 33 and 34: First Name Last Name Affiliation Ad
Page 37 and 38: EURO-NanoTox European Center for Na
Page 39 and 40: silver nanoparticles, iron nanopart
Page 41 and 42: The core functions of the Center, h
Page 43: 8 Directory Table 1 Directory of pe
Page 47 and 48: High Resolution Electron Microscopy
Page 49 and 50: integrated risk assessment. Integra
Page 51 and 52: powders: What is the difference in
Page 57 and 58: InLiveTox Intestinal, Liver and End
Page 59 and 60: - to develop and validate a novel m
Page 61 and 62: environments, IEEE Industrial Elect
Page 63 and 64: INSTANT Innovative Sensor for the f
Page 65 and 66: complementary research which will l
Page 67 and 68: 7 Copyright NanoSafetyCluster - Com
Page 69 and 70: ITS-NANO Intelligent testing strate
Page 71 and 72: approach to conveying the appropria
Page 73 and 74: in the discussion. The integration
Page 75 and 76: MARINA MANAGING RISKS of NANOMATERI
Page 77 and 78: for risk analysis, these tools need
Page 79 and 80: environmental ENM toxicity, but tox
Page 81 and 82: propose it as a Method Validation F
Page 83 and 84: and SiO2-NM200 and NM203, and a SiO
Page 85 and 86: ModNanoTox Modelling nanoparticle t
Page 87 and 88: 3) To model environmental exposure
Page 89 and 90: Nanodetector European Network on th
Page 91 and 92: measurement interval. Measurements
Page 93 and 94: 5 Directory Table 1 Directory of pe
Page 95 and 96:
NANODEVICE Novel Concepts, Methods,
Page 97 and 98:
ENP in order to be sure of their sa
Page 99 and 100:
4.3 Exploring the association betwe
Page 101 and 102:
NanoSafetyCluster - Compendium 2012
Page 103 and 104:
NanoFATE Nanoparticle Fate Assessme
Page 105 and 106:
or proteins associated with particu
Page 107 and 108:
sludge. Information on rates of slu
Page 109 and 110:
The exposures to be conducted will
Page 111:
NanoFATE progression beyond the “
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
NanoSafetyCluster ‐ Compendium 20
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288:
show all

Timing, hosts and locations of (grouped) events of NanoImpactNet

Create successful ePaper yourself

Delete template?

Save as template?